Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences non-GAAP SG&A expenses as % of total revenues (%) (%)
Form 8-K Non-GAAP Financial Information
Latest, FY2025
19.1%
Period ended Dec 31, 2025
Change on a year earlier
-1.4 pts
20.5% in FY2024
History
6 years
Since FY2020
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP SG&A expenses as % of total revenues (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19.1% | -1.4 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2024 | Dec 31, 2024 | 20.5% | -1.8 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2023 | Dec 31, 2023 | 22.3% | +1.8 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗ |
| FY2022 | Dec 31, 2022 | 20.5% | +2.3 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗ |
| FY2021 | Dec 31, 2021 | 18.2% | -1.4 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 19.6% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Non-GAAP SG&A expenses as % of total revenues (%) (%), annual FY2020–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng_sga_pct_rev
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.